Deals
Abbott said Exact Sciences will operate as a subsidiary following the transaction. The acquisition adds a business generating more than $3bn in annual revenue to Abbott’s diagnostics portfolio.
Danaher paid $9.9bn for Masimo. Abbott committed to Exact Sciences. Boston Scientific reached for Penumbra. Medtronic accelerated on multiple fronts. The window medtech spent two years waiting for is open – and the industry is moving through it fast.
The combined entity will employ more than 20,000 people across more than 100 countries, hold close to 3,000 patents, and bring together more than 700 R&D professionals.
Paradromics has launched a new academic-industry collaboration with leading brain-computer interface researchers at Stanford, Mass General, Pitt, UC Davis and Michigan aiming to translate BCI research into devices to help people with speech impairment, stroke and Parkinson’s.
SS Innovations said the net proceeds from the financing will be directed toward working capital and general corporate purposes, with a focus on advancing global expansion efforts across existing and target markets.
The acquisition adds an immunohistochemistry antibody, reagent and instrument portfolio to Agilent's pathology offering, expanding its clinical and research lab client groups.
Vitestro raised an oversubscribed $70M Series B to scale its autonomous blood-drawing system across the Netherlands and expand into Europe. The CE-marked robot has been tested in more than 10,000 patients, and the company is pursuing FDA clearance to enter the US market.
This acquisition is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and accretive thereafter.
An interactive look at medtech and diagnostics deals made during February 2026. Data courtesy of Biomedtracker.
RadNet's CEO Berger sees little overlap with GE's Intelerad deal, which he argues is a PACS viewer – not a true AI rival. DeepHealth, he believes, has the potential to transform the radiology workflow.
New Precision IO Group CEO Kurt Azarbarzin outlines the near-term strategy for Quantum Surgical’s robotic-assisted ablation platform and NeuWave Medical’s microwave technology. Quantum recently acquired NeuWave, but the companies will continue to operate independently.
Hims&Hers announced plans to acquire digital health company Eucalyptus for up to $1.15bn.
Under the terms of the agreement, Danaher will acquire all outstanding Masimo shares for $180 per share in cash. The company plans to finance the deal through a combination of cash on hand and proceeds from debt financing.
An interactive look at medtech and diagnostics deals made during January 2026. Data courtesy of Biomedtracker.
Medtronic has agreed to acquire Cathworks for up to $585m, converting a long-standing partnership into full ownership as it expands its footprint in coronary physiology and AI-enabled cardiovascular tools.
BioStem Technologies’ buyout of BioTissue Holding’s surgical and wound-care business adds cryopreserved and sterile technologies, Cryotek and SteriTek, and a direct sales force focused on acute care settings.
Boston Scientific’s $14.5bn Deal Folds Penumbra Thrombectomy Platforms Into Cardiovascular Franchise
Subject to shareholder approval,Boston Scientific will acquire Penumbra for approximately $11bn in cash on hand and new debt, and issue 41 million shares for the remaining $4bn.
The market is assessing how the blocked JenaValve transaction affects Edwards Lifesciences’ longer-range growth, particularly following targets laid out at the company’s December 2025 investor day.
An interactive look at medtech and diagnostics deals made during December 2025. Data courtesy of Biomedtracker.
Our experts said investor confidence in medtech is recovering as we head into 2026. Expect larger, selective fundraising and heightened M&A activity, focusing on innovative firms in neurology, cardiovascular health, and AI-driven technologies. Companies with solid strategies are favored.